Author of the critically acclaimed NewYork Times best seller The WorldWithout Us, Alan Weisman is anaward-winning journalist whose reportshave appeared in HarperÄôs, the NewYork Times Magazine, Atlantic Monthly,Discover, and Orion, among others,and on National Public Radio. A formercontributing editor to the Los AngelesTimes Magazine, he is a senior radioproducer for Homelands Productionsand teaches international journalism atthe University of Arizona. He lives inwestern Massachusetts.
David Spiegelhalter
Sir David Spiegelhalter has been Winton Professor of the Public Understanding of Risk at the University of Cambridge since October 2007. His background is in medical statistics, with an emphasis on Bayesian methods: his MRC team developed the BUGS software which has become the primary platform for applying modern Bayesian analysis using simulation technology. He has worked on clinical trials and drug safety and consulted and taught in a number of pharmaceutical companies, and also collaborates on developing methods for health technology assessment applicable to organisations such as NICE. His interest in performance...
Alan Weisman
Author of the critically acclaimed NewYork Times best seller The WorldWithout Us, Alan Weisman is anaward-winning journalist whose reportshave appeared in HarperÄôs, the NewYork Times Magazine, Atlantic Monthly,Discover, and Orion, among others,and on National Public Radio. A formercontributing editor to the Los AngelesTimes Magazine, he is a senior radioproducer for Homelands Productionsand teaches international journalism atthe University of Arizona. He lives inwestern Massachusetts.
David Spiegelhalter
Sir David Spiegelhalter has been Winton Professor of the Public Understanding of Risk at the University of Cambridge since October 2007. His background is in medical statistics, with an emphasis on Bayesian methods: his MRC team developed the BUGS software which has become the primary platform for applying modern Bayesian analysis using simulation technology. He has worked on clinical trials and drug safety and consulted and taught in a number of pharmaceutical companies, and also collaborates on developing methods for health technology assessment applicable to organisations such as NICE. His interest in performance...